Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.
Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, Escherich G, Feuchtinger T, Kosasih HJ, Khaw SL, Ekert PG, Pombo-de-Oliveira MS, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer RP, Fazio G, Cazzaniga G, Larghero P, Emerenciano M, Marschalek R. Meyer C, et al. Among authors: feuchtinger t. Leukemia. 2019 Sep;33(9):2306-2340. doi: 10.1038/s41375-019-0451-7. Epub 2019 Mar 21. Leukemia. 2019. PMID: 30899083 Free PMC article. No abstract available.
Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT.
Maier CP, Klose C, Seitz CM, Heubach F, Döring M, Meisel R, Schuster F, Gruhn B, Keller F, Rabsteyn A, Arendt AM, Amorelli G, Eichholz T, Feuchtinger T, Martinius H, Nierkens S, Teltschik R, Schulte JH, Lengerke C, Handgretinger R, Lang P. Maier CP, et al. Among authors: feuchtinger t. Blood Adv. 2024 May 14;8(9):2160-2171. doi: 10.1182/bloodadvances.2023011016. Blood Adv. 2024. PMID: 38290133 Free PMC article.
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Schramm F, et al. Among authors: feuchtinger t. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3. Leuk Lymphoma. 2019. PMID: 29966458 Clinical Trial.
Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.
Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle T, Rohlfs M, Binder V, Klein C, Feuchtinger T. Blaeschke F, et al. Among authors: feuchtinger t. Leukemia. 2020 Oct;34(10):2607-2620. doi: 10.1038/s41375-020-0793-1. Epub 2020 Mar 13. Leukemia. 2020. PMID: 32203137
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL.
Babor F, Peters C, Manser AR, Glogova E, Sauer M, Pötschger U, Ahlmann M, Cario G, Feuchtinger T, Gruhn B, Güngör T, Horn PA, Kremens B, Lang P, Mezger M, Müller I, Mytilineos J, Oevermann L, Pichler H, Scherenschlich N, Schuster FR, Siepermann M, Stachel D, Strahm B, Wössmann W, Escherich G, Zimmermann M, Schrappe M, Borkhardt A, Eckert C, Bader P, Uhrberg M, Meisel R. Babor F, et al. Among authors: feuchtinger t. Bone Marrow Transplant. 2019 Nov;54(11):1847-1858. doi: 10.1038/s41409-019-0543-z. Epub 2019 May 14. Bone Marrow Transplant. 2019. PMID: 31089287 Clinical Trial.
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer ML, Pieters R, Horstmann MA, Janka-Schaub GE, Escherich G. Schramm F, et al. Among authors: feuchtinger t. Blood Adv. 2019 Nov 26;3(22):3688-3699. doi: 10.1182/bloodadvances.2019000576. Blood Adv. 2019. PMID: 31765480 Free PMC article.
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Spohn M, Zimmermann M, Horstmann MA. Escherich G, et al. Among authors: feuchtinger t. Haematologica. 2022 May 1;107(5):1026-1033. doi: 10.3324/haematol.2021.279357. Haematologica. 2022. PMID: 34348455 Free PMC article. Clinical Trial.
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: feuchtinger t. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Wirth AK, Wange L, Vosberg S, Henrich KO, Rausch C, Özdemir E, Zeller CM, Richter D, Feuchtinger T, Kaller M, Hermeking H, Greif PA, Senft D, Jurinovic V, Bahrami E, Jayavelu AK, Westermann F, Mann M, Enard W, Herold T, Jeremias I. Wirth AK, et al. Among authors: feuchtinger t. Leukemia. 2022 Dec;36(12):2863-2874. doi: 10.1038/s41375-022-01726-7. Epub 2022 Nov 4. Leukemia. 2022. PMID: 36333584 Free PMC article.
140 results